Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ANTARES PHARMA (NQ: ATRS)
4.090 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 3:42 PM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about ANTARES PHARMA
 
< Previous 1 2 3 4 5 6 Next >
Antares Pharma Reports First Quarter 2008 Financial and Operating Results
May 15, 2008
from Business Wire News Releases
Antares Pharma to Report 2008 First Quarter Financial Results on May 15, 2008
May 06, 2008
from Business Wire News Releases
Antares Pharma's Partner to Initiate Phase III Trial for CNS Therapy in Q4 2008
April 15, 2008
ATD(TM) Gel Formulation of Ropinirole for the Treatment of Restless Legs Syndrome Read More
from Business Wire News Releases
Antares Pharma Announces Issuance of Key Patent Covering ATD(TM) Technology
April 07, 2008
from Business Wire News Releases
Antares Pharma Reports Fourth Quarter and Year End 2007 Financial and Operating Results
March 26, 2008
2007 Total Revenue and Product Revenue Increased 84% and 46% Read More
from Business Wire News Releases
Antares Pharma to Report 2007 Results on March 26, 2008
March 10, 2008
from Business Wire News Releases
Antares Pharma Appoints Kaushik J. Dave, PhD, R.Ph., MBA. as Vice President of Clinical and Regulatory Affairs
March 04, 2008
from Business Wire News Releases
Antares Receives Positive Guidance for European Registration
February 12, 2008
Testosterone ATD(TM) Gel Registration Plan Clarified by EMEA Read More
from Business Wire News Releases
Antares Pharma to Present at BIO CEO & Investor Conference 2008
February 05, 2008
from Business Wire News Releases
Antares Pharma Develops Novel Pen Injector under New Agreement with Teva Pharmaceuticals
January 07, 2008
Exclusive License, Development and Supply Agreement Read More
from Business Wire News Releases
Antares Pharma Receives Milestone Payment
December 19, 2007
Additional Potential of $10 Million in Sales Based Milestones Read More
from Business Wire News Releases
Antares Pharma to Present at BMO Capital Markets Focus on Healthcare Conference
November 28, 2007
from Business Wire News Releases
Antares Pharma and Population Council Announce Phase I Results
November 28, 2007
First Transdermal Contraceptive Gel Contains Nestorone(R) Read More
from Business Wire News Releases
Antares Pharma Reports Third Quarter 2007 Financial Results and Operating Progress
November 13, 2007
-- Q3 product revenue increases 90% and total revenue increases 63% above 2006 -- 2 new CNS/Pain product development and license agreements executed -- Initiation of Pivotal trial for ANTUROL(TM) Read More
from Business Wire News Releases
Antares Pharma to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
October 29, 2007
from Business Wire News Releases
Antares Pharma Doses First Patients in Pivotal Trial of ANTUROL(TM)
October 22, 2007
from Business Wire News Releases
Antares' Product Development Agreement Wins 2007 Innovative Bio-Partnering Award
October 16, 2007
Treating a Significant CNS Disorder Read More
from Business Wire News Releases
Antares Executes First EasyTec(TM) Life Cycle Extension Development and License Agreement
October 11, 2007
from Business Wire News Releases
Antares Reports Product Progress in Growing Women's Health Portfolio
October 02, 2007
Testosterone ATD(TM) Gel Development Pathway Clarified by FDA Read More
from Business Wire News Releases
Antares Pharma to Present at BIO InvestorForum 2007
September 26, 2007
from Business Wire News Releases
Antares Pharma to Present at William Blair Small-Cap Growth Stock Conference
September 20, 2007
from Business Wire News Releases
Antares Pharma to Present at UBS Global Life Sciences Conference
September 17, 2007
from Business Wire News Releases
Antares Pharma Will Present ANTUROL(TM) at the 28th Annual Scientific Meeting of the American Urogynecologic Society
August 28, 2007
from Business Wire News Releases
Antares Announces Initiation of Pivotal Trial of ANTUROL(TM) for the Treatment of Overactive Bladder
August 23, 2007
from Business Wire News Releases
Antares Pharma Reports Second Quarter 2007 Financial and Operating Results
August 13, 2007
-- Q2 product revenue increase of 77% and total revenue increase of 110% above 2006 -- Solid progress made in key ATD(TM) gel products, including launch of Elestrin(TM) -- Strong cash position Read More
from Business Wire News Releases
Antares Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Trial of Anturol(TM)
July 25, 2007
from Business Wire News Releases
Antares Announces Worldwide Development and License Agreement with Jazz Pharmaceuticals
July 19, 2007
from Business Wire News Releases
Antares Pharma Announces Closing of $16 Million Private Placement
July 10, 2007
from Business Wire News Releases
Antares Pharma Announces Agreement to Raise $15 Million in a Private Placement
June 29, 2007
from Business Wire News Releases
Antares Pharma Announces Commercial Launch of Its First Gel Based Pharmaceutical Product
June 13, 2007
Elestrin(TM), a Low Dose ATD(TM) Transdermal Estradiol Gel Read More
from Business Wire News Releases
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here